The findings to date indicate that GEP44 is a promising drug that overcomes the adverse side effects associated with existing GLP-1R agonist medications [5,46] to treat obesity and/or T2DM. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.